TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06390319: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia

Sponsor: St. Jude Children's Research Hospital · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06390319 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06390319 Rescue Dossier →